Pfizer Beats Falling Profit as the Dow Bounces Back From Recent Losses

DuPont falls to the bottom of the Dow despite a solid earnings report, but the blue-chip index rises behind Pfizer and climbing consumer confidence

Jan 28, 2014 at 2:30PM

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

The market's recent losses have petered out today, with the Dow Jones Industrial Average (DJINDICES:^DJI) gaining 88 points as of 2:30 p.m. EST. The Dow piggybacked on a Conference Board report that showed consumer confidence rose more than three points this month, to 80.7. That optimism helped fuel gains across most blue-chip stocks on the Dow. However, no stock's having quite a day like Pfizer (NYSE:PFE), which is up more than 3% behind an optimistic look toward the new year. Let's catch up on what you need to know.

Pfizer's earnings fall, but outlook soars
Pfizer has struggled with the patent cliff lately as its former best-selling cholesterol-fighting drug Lipitor lost patent protection in 2012. That's taken down Pfizer's sales over the past year, including a more than 2% slide in the company's most recent quarter -- although the strengthening dollar hurt Pfizer on currency-related impacts. Pfizer's recent trend of divesting noncritical business units also affected the company's overall performance, as net profit fell 59% for the quarter relative to a major one-time earnings bounce in the year-ago quarter from the sale of its infant nutrition business.

Still, analysts had expected less out of Pfizer, so the earnings beat combined with a solid look ahead has propelled the stock's gain today. Pfizer projects revenue of between $49.2 billion and $51.2 billion in 2014, a range that looks favorable compared to the average analyst estimate of $49.5 billion, as polled by Bloomberg.

Pfizer's strong drug pipeline has impressed analysts in the past, and the company will need to rely on its up-and-coming products as the patent cliff's effects, particularly from the Lipitor loss, begin to wane. Recently approved rheumatoid arthritis drug Xeljanz continues to sell slowly despite once garnering annual peak sales estimates of about $3 billion. Pfizer will need more from the drug and from fellow  potential blockbuster Eliquis.

Earnings season's a fickle thing on the Dow Jones. While Pfizer's stock has made the most of it today, the same can't be said for DuPont (NYSE:DD). The chemicals giant has fallen to the bottom of the Dow today in losing nearly 1% after it reported adjusted fourth-quarter earnings per share of $0.59, $0.04  ahead of the average analyst estimate. Revenue just missed the expected mark at $7.7 billion for the quarter, but that still represented a year-over-year gain of 6%. With a 14% growth out of DuPont's agricultural business, the company's earnings report should be impressing investors – not disappointing with a Dow-bottoming drop.

Don't wait to make the most of your financial future
Pfizer and other stocks have made the most of the market's recent rally, but have you earned your share? Millions of Americans have waited on the sidelines since the market meltdown in 2008 and 2009, too scared to invest and put their money at further risk. Yet those who've stayed out of the market have missed out on huge gains and put their financial futures in jeopardy. In our brand-new special report, "Your Essential Guide to Start Investing Today," The Motley Fool's personal finance experts show you why investing is so important and what you need to do to get started. Click here to get your copy today -- it's absolutely free.

Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers